IP Library Granted Patent US 12,378,531
Granted Patent B2
US 12,378,531 · App. 17/241,651 · Granted Aug 5, 2025

Use of RNA for reprogramming somatic cells

Inventors: Ugur Sahin (Mainz, DE); Marco Poleganov (Frankfurt, DE); Tim Beissert (Griesheim, DE)
Assignee: BIONTECH SE
C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,531
App. No.
17/241,651
Granted
Aug 5, 2025
Kind
B2
Abstract

Methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, include the steps of introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.

Claims (9)

1. A cell population which comprises (i) RNA-transfected somatic cells subjected to electroporation, the RNA-transfected somatic cells containing in vitro transcribed mRNA encoding OCT4, SOX2, KLF4 and c-MYC, wherein the mRNA comprises a 5′-Cap structure and wherein the RNA-transfected cells express alkaline phosphatase and endogenous OCT4, and (ii) somatic cells not subjected to electroporation.

2. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are human cells transfected with RNA.

3. The cell population in accordance with claim 2 , wherein the human cells are adult human dermal fibroblasts transfected with RNA.

4. The cell population in accordance with claim 1 , wherein the somatic cells subjected to electroporation are fibroblasts.

5. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells express endogenous OCT4 for at least 7 days.

6. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are fibroblasts deposited at American Type Culture Collection under Catalog No. CCL-186 and subsequently transfected with RNA.

7. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are fibroblasts deposited at American Type Culture Collection under Catalog No. CRL-2097 and subsequently transfected with RNA.

8. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are derived by RNA-transfection of fibroblasts deposited at American Type Culture Collection under Catalog No. CCL-186.

9. The cell population in accordance with claim 1 , wherein the RNA-transfected somatic cells are derived by RNA-transfection of fibroblasts deposited at American Type Culture Collection under Catalog No. CRL-2097.

Assignments (1)
CHANGE OF NAME Recorded Jun 16, 2021
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 056612/0563 →
Priority Claims (1)
EP 07024312 · Dec 14, 2007 · regional
Continuity (5)
Continuation 16250366 · Jan 17, 2019
Continuation 15485601 · Apr 12, 2017
Continuation 14933840 · Nov 5, 2015
Continuation 12735060
Related Publication 20210324341A1 · Oct 21, 2021
References Cited (2)
US 8058065B2 · Yamanaka · 2011 [cited by examiner]
WO WO2008097926A2 · 2008 [cited by examiner]